⌕
Solid Biosciences · SLDB · Nasdaq
Tenet 58 · Mixed
Compare
$6.84−2.29%At closeTenet 58 · Mixed
$6.84−0.16 (−2.29%)
At close: Nov 13, 2026, 4:00 PM ET· Nasdaq · USD

Solid Biosciences (SLDB) Stock

Solid Biosciences (SLDB) closed at $6.84 on Nov 13, 2026; its Tenet Score is 58 of 100 against 409 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

Key stats

Previous close
$6.84
Nov 13, 2026
Market cap
$763.4M
share price × the latest quarter's diluted weighted-average share count (vendor)
Dividend yield
0.00%
reinvests all
52-week range
4.16 – 11.45
low → high
Tenet Score
58/100
Mixed · 409 Healthcare peers

Industry: Health Services · see every company filed here →

Solid Biosciences Inc scores 58/100. Mixed. Strongest on financial health and value, quality is the soft spot versus 409 Healthcare peers. Insufficient inputs: Tenet 58 is built from 3 of 4 pillars, from 35% of its inputs. The pillars showing a dash had no data.

Tenet Score · vs sector

n=409
58/ 100
Mixed
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
74
Quality
14
Health
86
Growth
—

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
Growth omitted — no data yet.
ValueBQualityFHealthBGrowth—MomentumC
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Not meaningful: the company made a loss.
P/B
2.2×
cap ÷ Sep 30, 2026 book value, Nov 13, 2026 close
P/S
—
no P/S on file
ROE
−77%
TTM through Sep 30, 2026
Operating margin
—
no operating margin on file
Net margin
—
Not reported in the company's filings for this period.
Current ratio
11.99
Sep 30, 2026 balance sheet
Net debt / EBITDA
—
Not meaningful: EBITDA is zero or negative.
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.

The whole report, at a glance · every card is a live peek, click any to open the section

About Solid Biosciences Inc

Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin p…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=409) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 59 US ETFs · top wrappers by weightSee all ETFs holding SLDB →

Similar-sized companies in Health Services

The 10 companies in this industry closest in market cap, as of Nov 13, 2026.

What sector and industry is Solid Biosciences in?

Solid Biosciences is in the Healthcare sector and the Health Services industry.

What is Solid Biosciences' Tenet Score?

Solid Biosciences' Tenet Score is 58 out of 100, ranked against 409 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.